Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

XLO - Xilio Therapeutics, Inc.


IEX Last Trade
1.05
0   0%

Share volume: 100
Last Updated: Fri 10 Jan 2025 06:05:07 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): -0.49%

PREVIOUS CLOSE
CHG
CHG%

$1.05
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
6%
Profitability 0%
Dept financing 36%
Liquidity 24%
Performance 0%
Company vs Stock growth
vs
Performance
5 Days
-1.79%
1 Month
13.54%
3 Months
41.75%
6 Months
8.91%
1 Year
61.12%
2 Year
-58.65%
Key data
Stock price
$1.05
P/E Ratio 
0.00
DAY RANGE
$1.05 - $1.05
EPS 
$0.00
52 WEEK RANGE
$0.59 - $1.93
52 WEEK CHANGE
$61.12
MARKET CAP 
34.621 M
YIELD 
N/A
SHARES OUTSTANDING 
43.952 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.72
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$514,865
AVERAGE 30 VOLUME 
$1,155,786
Company detail
CEO: René Russo
Region: US
Website: xiliotx.com
Employees: 70
IPO year: 2021
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Xilio Therapeutics, Inc. develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate.

Recent news